and registry studies dealing with $100 carotid endovascular procedures in average-risk symptomatic patients with 50% to 99% North American Symptomatic Carotid Endarterectomy Trial (NASCET) stenosis were included. Two reviewers independently extracted data on study characteristics and perioperative outcomes. Discrepancies were resolved by a third, experienced reviewer. The primary end point was 30-day stroke or death incidence, and the secondary end point was 30-day all-cause mortality. Statistical analysis of registry studies followed a linear regression model, whereas visual inspection of a scatterplot alone was used for RCTs due to small number of studies. The Consolidated Standards of Reporting Trials principles were used to assess reporting of the studies, and The Cochrane Collaboration Tool was used to assess risk of bias.
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Results: Four RCTs (n ¼ 2381 procedures) and 29 registry studies (n ¼ 8335 procedures) reporting data between 1993 and 2012 were included in the quantitative analysis. Registry studies revealed a decreasing trend in 30-day stroke or death incidence (Fig 3) , and an increasing trend in 30-day all-cause mortality over a 19 year period (Fig 4) . The reduction in 30-day stroke or death incidence was equivalent to a e0.019% mean annual decrease (95% confidence interval, e 044 to 0.056; P ¼ .12, Fig 3) . The increase in 30-day all-cause mortality represented a 0.055% mean annual increase (95% confidence interval, e 0.04 to 0.15; P ¼ .024, Fig 4) . RCT data revealed a similar visual trend (Figs 1 and 2) .
Conclusions: The perioperative safety of carotid endovascular treatment in average-risk symptomatic patients has not changed significantly over past 20 years. The current evidence is not supportive of a change in clinical guidelines and commissioning of stroke services. Objectives: Timing of carotid revascularization in symptomatic patients is a matter of ongoing debate. Current evidence indicates that urgent (within 14 days of symptoms) carotid endarterectomy (CEA) is superior to delayed treatment. However, there is little evidence regarding the outcomes of emergent CEA (eCEA). The purpose of this study was to compare outcomes of eCEA (performed within a short interval of time after onset of symptoms during the same admission) vs nonemergent CEA.
Methods: We analyzed the VascularTargeted American College of Surgeons-National Surgical Quality Improvement Program (ACS-NSQIP) data set from 2011 to 2015. Symptomatic patients were divided into two groups; eCEA and non-eCEA. Univariate (t-test, c 2 , Fisher exact test) and multivariate (logistic regression) methods were used to compare patient characteristics and to evaluate stroke, death, myocardial infarction (MI), stroke/death, and stroke/death/MI within 30 days of surgery adjusting for all potential confounders (Table I) . Further subgroup analysis was done to compare the outcomes of eCEA vs non-eCEA stratified by the type of presenting symptoms.
Results: A total of 7579 patients were identified, of which 397 had undergone eCEA vs 7182 non-eCEA. The mean age was similar in both groups (70 6 11.2 vs 70.9 6 9.9 years; P ¼ .09). The majority of patients were males (64%). There were more white patients in the non-eCEA group (80% vs 56%; P < .001). Both groups had similar comorbidities but slight differences in degree of stenosis (Table II) . Thirty-day absolute outcomes (Table II) comparing eCEA vs non-eCEA were stroke: 6.6% vs 3.1% (P ¼ .001), death: 2.3% vs 1.1% (P ¼ .04), stroke/death: 7.6% vs 3.9% (P < .001), and stroke/death/MI: 9.1% vs 5.2% (P ¼ .001). After risk adjustment, perioperative stroke (odds ratio [OR], 2.10; 95% confidence interval [CI], 1.33-3.30; P ¼ .001), stroke/death (OR, 1.77; 95% CI, 1.15-2.73; P ¼ .009), and stroke/death/MI (OR, 1.66; 95% CI, 1.12-2.45; P ¼ .01) were higher after eCEA. When stratified by the type of presenting symptoms, patients undergoing eCEA with transient symptoms (transient ischemic attack/ amaurosis fugax) had significantly higher odds of stroke (OR, 2.97; 95% CI, 1.59-5.55; P ¼ .001), stroke/death (OR, 2.23; 95% CI, 1.21-4.12; P ¼ .01), and stroke/death/MI (OR: 1.88; 95% CI, 1.08-3.27; P ¼ .03). However, eCEA was not associated with any significant increase in stroke, death, or MI in patients presenting with stroke.
Conclusions: e-CEA can be done in patients presenting with stroke without additional risk of stroke and death. However, patients presenting with transient symptoms, such as transient ischemic attack or amaurosis fugax, are better served with non-eCEA as their risk of stroke is tripled when eCEA is performed. 
